Aerogen, the world leader in acute care aerosol drug delivery^1†, was honoured to sponsor the inaugural Dr. Jim Fink International Aerosol Medicine Training Program, a forward-thinking global initiative dedicated to elevating best practices in aerosol therapy.

Led by internationally renowned experts Dr. Jim Fink, a pioneer in aerosol drug delivery research, and Dr. Arzu Ari, a distinguished academic in respiratory care education, the program brought together 40 healthcare professionals from 25 countries. Many attendees were from developing nations, where access to world-class aerosol drug delivery education and training is often limited.

The intensive curriculum was designed to deepen participants’ understanding of respiratory care and inhalation therapy, with a strong focus on advancing clinical skills and practical expertise. Key areas of study included:

• Principles of Aerosol Drug Delivery
• Types and Use of Aerosol Delivery Devices
• Techniques for Spontaneously Breathing Patients in Acute Settings
• Aerosol Therapy in Critical Pulmonary Care
• Pediatric Aerosol Drug Delivery

This initiative reflects Aerogen’s commitment to advancing global respiratory care and is closely aligned with the company’s Pledge 1% initiative, dedicating 1% of company time and profits to support charitable programs and education across the communities in which it operates.

Feedback from attendees was overwhelmingly positive, underscoring the importance of providing high-quality training to clinicians who might not otherwise have access to such opportunities. By sharing expertise on the latest developments in aerosol therapy, the program is expected to contribute to better outcomes for patients worldwide.

As the global leader in this field, Aerogen is associated with over 300 clinical papers and publications¹.